- Home
- BDTX vs KZIA Comparison
BDTX vs KZIA Comparison
Compare BDTX & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | KZIA |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | Australia |
| Employees | N/A | 6 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 186.7M |
| IPO Year | 2020 | 2002 |
Fundamental Metrics
Financial Performance| Metric | BDTX | KZIA |
|---|---|---|
| Price | $2.09 | $11.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $9.67 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 506.7K | 255.7K |
| Earning Date | 05-08-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $4.86 |
| 52 Week High | $4.94 | $17.40 |
Technical Indicators
Market Signals| Indicator | BDTX | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 42.77 |
| Support Level | $1.98 | $11.39 |
| Resistance Level | $2.28 | $14.85 |
| Average True Range (ATR) | 0.10 | 1.11 |
| MACD | -0.02 | -0.26 |
| Stochastic Oscillator | 26.67 | 4.16 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.